OSUCCC – James Cancer Diagnostic Center speeds up diagnosis, treatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new center at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute gives patients direct, expedited access to diagnostic testing for cancer.

The center’s goal is to provide immediate community-wide patient access to cancer providers for anyone with a suspected cancer, especially in communities where access to healthcare is limited and has become more challenging during the COVID-19 pandemic.

The James Cancer Diagnostic Center offers a platform for expert evaluation and access to the appropriate diagnostic testing so that a cancer diagnosis can be made in a timely and precise manner, in a low-risk environment. Center visits can be virtual or in-person based on the patient’s preference.

Launched on June 15, the Cancer Diagnostic Center is open daily and staffed by a team of advanced practice professionals and nurses who have expertise in oncology. The team is overseen by physicians with oncology experience and expertise.

The center is available for both self- or physician-referral. Center staff first identify and prioritize patient needs and concerns and then coordinate appropriate testing and evaluation on behalf of the patient at facilities within The James and the Ohio State Wexner Medical Center. Follow-up care is also coordinated with a specialized, multidisciplinary team at The James if a cancer diagnosis is made.

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login